Isolated lung perfusion with tumor necrosis factor for pulmonary metastases

Annals of Thoracic Surgery

Volumn 61, Issue 6, 1996, Pages 1609-1617

  Pass, Harvey I ^a   Mew, Daphne J Y ^a   Kranda, Karen C ^a   Temeck, Barbara K ^a   Donington, Jessica S ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLEPHRINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DRUG BLOOD LEVEL; EWING SARCOMA; FEMALE; HEMODYNAMICS; HUMAN; HYPERTHERMIC THERAPY; INOPERABLE CANCER; INTENSIVE CARE; LUNG EDEMA; LUNG METASTASIS; LUNG PERFUSION; LUNG TOXICITY; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029890608     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00166-X     Document Type: Article

References (20)

1. Beutler B, Mahoney J, LeTrang N, et al. Purification of cachetin, a lipoprotein lipase-suppressing hormone secreted by endotoxin induced RAW 264.7 cells. J Exp Med 1985;161: 984-5.
2. Alexander RB, Rosenberg SA. Tumor necrosis factor: clinical applications. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer. Philadelphia: JB Lippincott, 1991: 378-92.
3. Asher A, Mulé JJ, Reichert CM, Shiloni A, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 1987;138:963-74.
4. Pogrebniak HW, Witt C, Terrill R, et al. Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 1994;57: 1477-83.
5. Pierpont H, Blades B. Lung perfusion with chemotherapeutic agents. J Thorac Cardiovasc Surg 1960;39:159-65.
6. Jacobs JK, Flexner JM, Scott HW Jr. Selective isolated perfusion of the right lung. J Thorac Cardiovasc Surg 1961;42: 546-52.
7. Johnston MR, Minchin R, Shull JH, et al. Isolated lung perfusion with adriamycin. A preclinical study. Cancer 1983; 52:404-9.
8. Johnston MR, Christensen CW, Minchin RF, et al. Isolated total lung perfusion as a means to deliver organ-specific chemotherapy: long-term studies in animals. Surgery 1985; 98:35-44.
9. Johnston MR, Minchen RF, Dawson CA. Lung perfusion with chemotherapy in patients with unresectable metastatic sarcoma to the lung or diffuse bronchioloalveolar carcinoma. Thorac Cardiovasc Surg 1995;110:368-73.
10. Rickaby DA, Fehring JF, Johnston MR, Dawson CA. Tolerance of the isolated perfused lung to hyperthermia. J Thorac Cardiovasc Surg 1991;101:732-9.
11. Baciewicz FA, Arredondo M, Chaudhuri B, et al. Pharmacokinetics and toxicity of isolated perfusion of lung with doxorubicin. J Surg Res 1991;50:124-8.
12. Weksler B, Schneider A, Ng B, Burt M. Isolated single lung perfusion in the rat: an experimental model. J Appl Physiol 1993;74:2736-9.
13. Leinard D, Lejeune F, Delmotte J, et al. High doses of rTNFα in combination with IFN-gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60.
14. Lienard D, Lejeune F, Ewalenko I. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 1992;16:234-40.
15. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for tumor necrosis factor and their regulation by gamma-interferon. Nature 1985;318:665-7.
16. Wedgwood JF, Hatam L, Benagora VR. Effect of Interferon and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical vein endothelial cells. Cell Immunol 1988;111: 1-9.
17. Niitsu Y, Watanabe N, Umeno H, et al. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastases. Cancer Res 1988;48:654-7.
18. Lo SK, Everitt J, Gu J, Malik AB. Tumor necrosis factor mediates experimental pulmonary edema by ICAM-1 and CD18-dependent mechanisms. J Clin Invest 1992;89:981-8.
19. Hocking DC, Phillips PG, Ferro TJ, Johnson A. Mechanisms of pulmonary edema induced by tumor necrosis factor-α. Circ Res 1990;67:68-77.
20. Fuchs HJ, Debs R, Patton JS, Liggitt HD. The pattern of lung injury induced after pulmonary exposure to tumor necrosis factor-a depends on the route of administration. Diagn Microbiol Infect Dis 1990;13:397-404.